前收市價 | 4.8900 |
開市 | 無 |
買盤 | 4.3500 |
賣出價 | 5.6000 |
拍板 | 70.00 |
到期日 | 2024-06-21 |
今日波幅 | 4.2800 - 4.8900 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 64 |
While it’s always a good idea to balance your portfolio with defensive stocks, the present chaos dramatically incentivizes this subsegment. As you’ve no doubt heard, the U.S. and the rest of the world presently reel from two major banks failing. Moreover, the main concern centers on the contagion spreading to other components of the global economy. What really adds weight to the drama here is of course the Federal Reserve. The central bank must decide how to navigate monetary policy in light of
https://cdn.benzinga.com/files/images/story/2023/03/17/mrk.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Merck & Co Inc's (NYSE: MRK) MK-7684A failed the open-label portion of a Phase 2 study KeyVibe-002 trial. MK-7684A, a combination of Keytruda (pembrolizumab) and in-house anti-TIGIT compound vibostolimab, did not improve patients' progression-free survival compared to chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) with progressive disease after treatment wit
In this article, we discuss 10 best psychedelic stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Psychedelic Stocks to Buy According to Hedge Funds. Data Bridge Market Research predicts that the psychedelic drugs market will expand at a compound annual growth rate […]